Another study on two HPV(+) and two HPV(−) HNSCC cell lines revealed that the PARP inhibitor niraparib enhanced their sensitivity to both photon and proton radiotherapy and increased the relative biological effectiveness (RBE) of protons, possibly by inhibiting DDR [210]. The gene discussed is PARP1; the disease is head and neck squamous cell carcinoma.